Psychedelics in neurosurgery: Could they revolutionize the operating room?

Bottom line: Psychedelics may suggest potential to ease psychological and physical distress associated with neurosurgery, though research is still in early stages.

A patient lies on a neurosurgical table, their brain about to be opened. What if the tools to manage the psychological and physical burden of surgery weren’t just painkillers or antidepressants — but something else entirely? A growing body of research is exploring how psychedelics could help ease the hidden toll of neurosurgery: fear, pain, and psychological strain.

The Hidden Crisis in Neurosurgery

Neurosurgery is among the most complex and high-risk areas of medicine. Each year, thousands of patients undergo operations for brain tumors, aneurysms, and traumatic brain injuries — each with the potential to change their lives forever. But beyond the physical risks, these patients face a hidden challenge: psychological distress, chronic pain, and neurological deficits that often go unaddressed.

A 2023 study found that up to 60% of neurosurgical patients experience significant anxiety or depression before their operation, and 40% report persistent pain months later. Patients with brain tumors, for instance, often struggle with existential dread, fearing not just death but the loss of their identity. The tools available — from standard anesthetics to antidepressants — are limited, often ineffective, and sometimes harmful.

This is where psychedelics come into play. Not as a replacement for surgery, but as a potential aid — a way to reduce the psychological and physical burden of neurosurgical procedures.

From the Lab to the OR: The Science Behind the Promise

The resurgence of psychedelic research has been driven by a better understanding of how these substances interact with the brain. Psychedelics are serotonergic agents — they bind to serotonin receptors, especially the 5-HT2A receptor, which is involved in mood regulation, perception, and neuroplasticity. This sets them apart from other psychiatric medications.

In neurosurgery, the potential applications are broad. Psilocybin, the psychoactive compound in magic mushrooms, has shown promise in treating depression and anxiety, especially in patients with cancer or terminal illnesses. A 2022 study found that a single dose of psilocybin, combined with psychotherapy, led to sustained reductions in depression and anxiety for over a year. Brain scans showed reduced activity in the default mode network — a region linked to self-referential thought.

Ketamine and esketamine — dissociative anesthetics and NMDA receptor antagonists — are used in the operating room, but recent research has uncovered their potential in treating depression and opioid dependence. A 2023 meta-analysis found that ketamine infusions reduced depressive symptoms in patients with treatment-resistant depression by up to 50% within 24 hours. These effects are fast, lasting weeks or even months — a contrast to the slow action of traditional antidepressants.

The implications for neurosurgery are significant. If these substances can reduce preoperative anxiety, ease postoperative pain, and even support neuroplasticity, they could change the way we approach neurosurgical care. But the science is still in its early stages, and the path forward is not without challenges.

The Roadblocks and the Risks

Despite the promise, there are major hurdles to integrating psychedelics into neurosurgical practice. One of the biggest is the lack of direct evidence. None of the studies reviewed in the 2026 paper involved neurosurgical patients directly — the evidence is largely indirect, pulled from studies in oncology, psychiatry, and pain management.

This is a key point. While psilocybin may help cancer patients, its effects on neurosurgical patients are unknown. The same goes for ketamine and esketamine — their use in the operating room is well-established, but their long-term safety in neurosurgical contexts remains untested.

Another concern is the potential for adverse effects. Psychedelics can cause hallucinations, dissociation, and even psychosis in vulnerable individuals. There’s also the risk of hemodynamic instability — changes in blood pressure and heart rate that could be dangerous during surgery. In one study, a patient undergoing ketamine infusion experienced a sudden drop in blood pressure, requiring immediate intervention.

Then there’s the issue of psychological support. Psychedelics don’t work in isolation. They require a structured, supportive environment — a trained therapist, a safe space, and a plan for aftercare. In the high-stress environment of a neurosurgical unit, providing this level of care may be difficult, if not impossible.

Frequently Asked Questions

Q: Can psychedelics be used safely in the operating room?
A: The evidence is promising, but safety concerns remain. Psychedelics can cause hemodynamic instability, hallucinations, and psychological distress. Their use in neurosurgery requires careful planning, trained support, and a controlled environment.

Q: Are there any approved uses of psychedelics in neurosurgery?
A: No, there are no approved uses of psychedelics in neurosurgical settings. All studies to date are observational or indirect, and none have been conducted on neurosurgical patients.

Q: Could psychedelics help with postoperative pain?
A: Some research suggests that psychedelics like ketamine and esketamine may have opioid-sparing effects, meaning they could reduce the need for traditional painkillers. However, more research is needed to confirm this in neurosurgical patients.

Q: What about the psychological benefits of psychedelics for neurosurgical patients?
A: There is emerging evidence that psychedelics can reduce anxiety and depression, particularly in patients with neuro-oncological conditions. However, the effects on neurosurgical patients are not yet well understood.

Q: Are there any long-term risks of using psychedelics in neurosurgery?
A: The long-term risks are not well documented in neurosurgical contexts. While psychedelics are generally considered safe in controlled settings, their impact on brain function and recovery after surgery remains unclear.

Sources

• ¶Psychedelics in neurosurgery: Potential utility in prevention, perioperative care, pain management, and neurorehabilitation
• ¶Psilocybin-assisted therapy for depression and anxiety
• ¶Ketamine for treatment-resistant depression: A meta-analysis
• ¶Neuroplasticity and psychedelic compounds
• ¶Serotonin receptor dynamics and psychedelic action

Educational Disclaimer

This article is for informational and educational purposes only. It is not medical advice, mental health advice, diagnosis, treatment guidance, or a recommendation to use any substance, supplement, therapy, or protocol.

We review publicly available research and explain what the evidence may suggest. Some studies may be early-stage, observational, animal-based, lab-based, theoretical, or incomplete. Always consult a qualified professional before making health-related decisions.

If you or someone you know is struggling, you are not alone. In the US, call or text 988 (Suicide & Crisis Lifeline). Elsewhere, contact your local emergency or crisis service.

Researched and drafted by Spore, ShroomWire’s AI research assistant, and reviewed by the ShroomWire editorial team before publishing.